

Overview

Useful For

Routine health monitoring

Patient monitoring while hospitalized for information regarding metabolism, including the current kidney status, electrolyte and acid/base balance, and blood glucose

Profile Information

Test Id	Reporting Name	Available Separately	Always Performed
KS	Potassium, S	Yes	Yes
NAS	Sodium, S	Yes	Yes
CL	Chloride, S	Yes	Yes
HCO3	Bicarbonate, S	Yes	Yes
AGAP	Anion Gap	No	Yes
BUN	Bld Urea Nitrog (BUN), S	Yes	Yes
CRTS1	Creatinine with eGFR, S	Yes	Yes
CA	Calcium, Total, S	Yes	Yes
GLURA	Glucose, Random, S	Yes	Yes
TP	Protein, Total, S	Yes	Yes
ALB	Albumin, S	Yes	Yes
AST	Aspartate Aminotransferase (AST), S	Yes	Yes
ALP	Alkaline Phosphatase, S	Yes	Yes
ALT	Alanine Aminotransferase (ALT), S	Yes	Yes
BILIT	Bilirubin Total, S	Yes	Yes

Method Name

KS, NAS, CL: Potentiometric, Indirect Ion-Selective Electrode
HCO3: Photometric/Enzymatic
AGAP: Calculation
BUN: Photometric, Urease
CRTS1: Enzymatic Colorimetric Assay
CA: Photometric,
GLURA: Enzymatic Photometric Assay
TP: Colorimetric, Biuret
ALB: Photometric, Bromcresol Green
AST: Photometric Rate, L-Aspartate with Pyridoxyl-5-Phosphate
ALP: Colorimetric
ALT: Photometric Rate, L-Alanine with Pyridoxal-5-Phosphate

BILIT: Photometric, Diazonium Salt

NY State Available

Yes

Specimen

Specimen Type

Serum

Shipping Instructions

Ship specimen protected from light.

Necessary Information

Patient's age and sex are required.

Specimen Required

Supplies: Amber Frosted Tube, 5 mL (T915)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Amber vial

Specimen Volume: 0.6 mL

Collection Instructions:

1. Serum gel tubes should be centrifuged and protected from light within 2 hours of collection.
2. Red-top tubes should be centrifuged, and the serum aliquoted into an amber vial within 2 hours of collection.

Specimen Minimum Volume

0.5 mL

Reject Due To

Gross hemolysis	Reject
Gross lipemia	OK

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated	24 hours	

Clinical & Interpretive

Clinical Information

The comprehensive metabolic panel measures 14 analytes and calculates an anion gap. It is used to assess kidney or liver status, electrolyte and acid/base balance, and blood glucose. This comprehensive metabolic panel can also provide information about a patient's response to medications that would impact kidney or liver function.

Reference Values**SODIUM**

<1 year: Not established
> or =1 year: 135-145 mmol/L

POTASSIUM

<1 year: Not established
> or =1 year: 3.6-5.2 mmol/L

CHLORIDE

1-17 years: 102-112 mmol/L
> or =18 years: 98-107 mmol/L

Reference values have not been established for patients who are younger than 12 months of age.

BICARBONATE**Males**

12-24 months: 17-25 mmol/L
3 years: 18-26 mmol/L
4-5 years: 19-27 mmol/L
6-7 years: 20-28 mmol/L
8-17 years: 21-29 mmol/L
> or =18 years: 22-29 mmol/L

Females

1-3 years: 18-25 mmol/L
4-5 years: 19-26 mmol/L
6-7 years: 20-27 mmol/L
8-9 years: 21-28 mmol/L
> or =10 years: 22-29 mmol/L

Reference values have not been established for patients that are younger than 12 months of age.

ANION GAP

> or =7 years: 7-15

Reference values have not been established for patients who are younger than 7 years of age.

BLOOD UREA NITROGEN (BUN)**Males**

1-17 years: 7-20 mg/dL
> or =18 years: 8-24 mg/dL

Reference values have not been established for patients who are younger than 12 months of age.

Females

1-17 years: 7-20 mg/dL

> or =18 years: 6-21 mg/dL

Reference values have not been established for patients who are younger than 12 months of age

CREATININE**Males:**

0-11 months: 0.17-0.42 mg/dL

1-5 years: 0.19-0.49 mg/dL

6-10 years: 0.26-0.61 mg/dL

11-14 years: 0.35-0.86 mg/dL

> or =15 years: 0.74-1.35 mg/dL

Females:

0-11 months: 0.17-0.42 mg/dL

1-5 years: 0.19-0.49 mg/dL

6-10 years: 0.26-0.61 mg/dL

11-15 years: 0.35-0.86 mg/dL

> or =16 years: 0.59-1.04 mg/dL

ESTIMATED GLOMERULAR FILTRATION RATE (eGFR)

>= 18 years old: > or =60 mL/min/BSA

Estimated GFR calculated using the 2021 CKD_EPI creatinine equation.

Note: eGFR results will not be calculated for patients younger than 18 years old.

CALCIUM

<1 year: 8.7-11.0 mg/dL

1-17 years: 9.3-10.6 mg/dL

18-59 years: 8.6-10.0 mg/dL

60-90 years: 8.8-10.2 mg/dL

>90 years: 8.2-9.6 mg/dL

GLUCOSE

0-11 months: Not established

> or =1 year: 70-140 mg/dL

TOTAL PROTEIN

> or =1 year: 6.3-7.9 g/dL

Reference values have not been established for patients who are younger than 12 months of age.

ALBUMIN

> or =12 months: 3.5-5.0 g/dL

Reference values have not been established for patients who are younger than 12 months of age.

ASPARTATE AMINOTRANSFERASE (AST)**Males:**

0-11 months: Not established

1-13 years: 8-60 U/L

> or =14 years: 8-48 U/L

Females:

0-11 months: Not established

1-13 years: 8-50 U/L

> or =14 years: 8-43 U/L

ALKALINE PHOSPHATASE (ALP)**Males**

0-14 days: 83-248 U/L

15 days-<1 year: 122-469 U/L

1-<10 years: 142-335 U/L

10-<13 years: 129-417 U/L

13-<15 years: 116-468 U/L

15-<17 years: 82-331 U/L

17-<19 years: 55-149 U/L

> or =19 years: 40-129 U/L

Females

0-14 days: 83-248 U/L

15 days-<1 year: 122-469 U/L

1-<10 years: 142-335 U/L

10-<13 years: 129-417 U/L

13-<15 years: 57-254 U/L

15-<17 years: 50-117 U/L

> or =17 years: 35-104 U/L

ALANINE AMINOTRANSFERASE (ALT)**Males:**

> or =1 year: 7-55 U/L

Reference values have not been established for patients who are younger than 12 months of age.

Females:

> or =1 year: 7-45 U/L

Reference values have not been established for patients who are younger than 12 months of age.

TOTAL BILIRUBIN0-6 days: Refer to www.bilitool.org for information on age-specific (postnatal hour of life) serum bilirubin values.

7-14 days: 0.0-14.9 mg/dL

15 days to 17 years: 0.0-1.0 mg/dL

>18 years 0.0-1.2 mg/dL

Interpretation

Comprehensive metabolic panel results are usually evaluated in conjunction with each other for patterns of results. The pattern of abnormal results can help identify the possible conditions or diseases present. Many conditions will cause abnormal results including kidney failure, breathing problems, and diabetes-related complications.

Cautions

No significant cautionary statements

Clinical Reference

Comprehensive Metabolic Panel (CMP). Testing.com; Updated July 29, 2022. Accessed September 19, 2023. Available at www.testing.com/tests/comprehensive-metabolic-panel-cmp/

Performance

Method Description

Sodium, Potassium, Chloride:

Ion-selective electrode (ISE) (indirect potentiometry). The ion selective electron (ISE) module indirectly measures the electromotive force (EMF) difference between an ISE and a reference electrode. The EMF of the ion-selective electrode is dependent on the ion concentration of the sample. The EMF of the reference electrode is constant. An electronic calculation circuit converts EMF of the sample to the ion concentration of the sample.(Package insert: ISE Indirect Na, K, CL for Gen2. Roche Diagnostics; 12/2020)

Bicarbonate:

This is a photometric rate reaction. Bicarbonate (HCO_3^-) reacts with phosphoenolpyruvate (PEP) in the presence of phosphoenolpyruvate carboxylase (PEPC) to produce oxaloacetate and phosphate. The oxaloacetate produced is coupled with NADH in the presence of malate dehydrogenase (MDH) to produce malate and NAD. The consumption of NADH causes a decrease in absorbance and is monitored in the UV range of 320 nm to 400 nm. The rate of change is directly proportional to the concentration of bicarbonate.(Package insert: Bicarbonate reagent Roche Diagnostics; 04/2019)

Anion Gap:

This is a calculated result. The following equation is used to calculate the anion gap (A gap):

$$\text{A gap} = \text{Na} - (\text{Cl} + \text{HCO}_3^-)$$

Blood Urea Nitrogen:

This is a kinetic UV assay where urease cleaves urea to form ammonia and carbon dioxide. The ammonia formed then reacts with alpha-ketoglutarate and NADH in the presence of urease/glutamate dehydrogenase to yield glutamate and NAD^+ . The decrease in absorbance, due to the consumption of NADH, is measured kinetically and is proportional to the amount of urea in the sample.(Package insert: Urea/BUN reagent. Roche Diagnostics; 12/2019)

Creatinine:

This enzymatic method is based on the conversion of creatinine with the aid of creatininase, creatinase, and sarcosine oxidase to glycine, formaldehyde, and hydrogen peroxide. Catalyzed by peroxidase the liberated hydrogen peroxide

reacts with 4-aminophenazone and HTIB ([hydroxy\[tosyloxy\]iodobenzene](#)) to form a quinone imine chromogen. The color intensity of the quinone imine chromogen formed is directly proportional to the creatinine concentration in the reaction mixture. (Package insert: Creatinine. Roche Diagnostics; 02/2019)

Calcium:

Calcium ions react with NM-BAPTA (5-nitro-5'-methyl-1,2-bis[o-aminophenoxy]ethane-N,N,N',N'-tetraacetic acid) under alkaline conditions to form a complex. This complex reacts in the second step with EDTA. The change in absorbance is directly proportional to the calcium concentration and is measured photometrically. (Package insert: Calcium Gen.2 reagent. Roche Diagnostics; 07/2019)

Glucose:

[Glucose in the serum, in the presence of hexokinase, is converted to glucose-6-phosphate \(G6P\). In the presence of nicotinamide adenine dinucleotide phosphate \(NADP+\), glucose-6-phosphate dehydrogenase oxidizes G6P to gluconate-6-phosphate and NADPH.](#) The rate of NADPH formation is directly proportional to glucose concentration and is measured photometrically. (Package insert: Glucose HK Gen.3 Reagent. Roche Diagnostics; 11/2021)

Total Protein:

Divalent copper reacts in alkaline solution with protein peptide bonds to form the characteristic purple-colored biuret complex. Sodium potassium tartrate prevents the precipitation of copper hydroxide and potassium iodide prevents autoreduction of copper. The color intensity is directly proportional to the protein concentration, which can be determined photometrically. (Package insert: Total Protein Gen.2 reagent, Roche Diagnostics; 11/2019)

Albumin:

The dye, bromocresol green (BCG), is added to serum in an acid buffer. The color intensity of the blue-green albumin-BCG complex is directly proportional to the albumin concentration and is determined photometrically. (Package insert: Albumin Gen.2 reagent. Roche Diagnostics; 02/2022)

Aspartate Aminotransferase:

Aspartate aminotransferase (AST) is measured by a coupled enzyme kinetic method where the rate of decrease of NADH, determined at 340 nm, is directly proportional to the AST activity. (Package insert: AST reagent. Roche Diagnostics; 02/2022)

Alkaline Phosphatase:

In the presence of magnesium and zinc ions, p-nitrophenyl phosphate is cleaved by phosphatases into phosphate and p-nitrophenol. The p-nitrophenol released is directly proportional to the catalytic alkaline phosphatase activity. It is determined by measuring the increase in absorbance. (Package insert: Alkaline Phosphatase Gen.2 reagent. Roche Diagnostics; 04/2019)

Alanine Aminotransferase:

Alanine aminotransferase (ALT) activity is determined by a kinetic method using a coupled enzyme reaction where the rate of NADH consumption is measured at 340 nm. The NADH decrease is directly proportional to the ALT activity. (Package insert: ALT reagent. Roche Diagnostics; 11/2021)

Total Bilirubin:

Total bilirubin, in the presence of a suitable solubilizing agent, is coupled with 3,5-dichlorophenyl diazonium in a strongly

acidic medium. The color intensity of the red azo dye formed is directly proportional to the total bilirubin and can be determined photometrically.(Package insert: Bilirubin Total Gen. 3. Roche Diagnostics; 01/2020)

PDF Report

No

Day(s) Performed

Monday through Sunday

Report Available

Same day/1 to 2 days

Specimen Retention Time

1 week

Performing Laboratory Location

Rochester

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

- KS-84132
- NAS-84295
- CL-82435
- HCO3-82374
- BUN-84520
- CRTS1-82565
- CA-82310
- GLURA-82947
- TP-84155
- ALB-82040
- AST-84450
- ALP-84075
- ALT-84460

BILIT-82247

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
CMAMA	Comprehensive Metabolic Panel, S	24323-8

Result ID	Test Result Name	Result LOINC® Value
AGAP	Anion Gap	33037-3
ALB	Albumin, S	1751-7
ALP	Alkaline Phosphatase, S	6768-6
ALT	Alanine Aminotransferase (ALT), S	1743-4
AST	Aspartate Aminotransferase (AST), S	30239-8
BILIT	Bilirubin Total, S	1975-2
BUN	Bld Urea Nitrog (BUN), S	3094-0
CL	Chloride, S	2075-0
GLURA	Glucose, Random, S	2345-7
HCO3	Bicarbonate, S	1963-8
TP	Protein, Total, S	2885-2
CA	Calcium, Total, S	17861-6
NAS	Sodium, S	2951-2
KS	Potassium, S	2823-3
CRTSA	Creatinine, S	2160-0
EGFR1	Estimated GFR (eGFR)	98979-8